BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lymphoma AND FOXL2, BPES, 668, ENSG00000183770, P58012, PFRK, POF3, PINTO, BPES1 AND Treatment
25 results:

  • 1. Risk and Severity of COVID-19 Infection in Monoclonal Gammopathy of Undetermined Significance: A 3-Year Propensity Matched Cohort Study.
    Ashruf OS; Orozco Z; Kaelber DC
    Clin Lymphoma Myeloma Leuk; 2023 Aug; 23(8):626-632. PubMed ID: 37208255
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Long term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas Cancer Registry.
    Burns EA; Sanchez CG; Mathur S; Guerrero C; Muhsen IN; Sarfraz H; Hu CA; Tang CA; Shah SS; Tremont IW; Teh B; Ganguly S; Pingali SRK
    Ann Hematol; 2023 May; 102(5):1111-1120. PubMed ID: 36922432
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Role of Local treatment for Oligometastasis: A Comparability-Based Meta-Analysis.
    Rim CH; Cho WK; Lee JH; Kim YS; Suh YG; Kim KH; Chie EK; Ahn YC;
    Cancer Res Treat; 2022 Oct; 54(4):953-969. PubMed ID: 35989655
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Inpatient treatment of relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): A health economic perspective.
    Moertl B; Dreyling M; Schmidt C; Hoster E; Schoel W; Bergwelt-Baildon MV; Berger K
    Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):474-482. PubMed ID: 35033478
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Conversion to supportive care with biosimilar pegfilgrastim-cbqv enables budget-neutral expanded access to R-CHOP treatment in non-Hodgkin lymphoma.
    McBride A; MacDonald K; Abraham I
    Leuk Res; 2021 Jul; 106():106591. PubMed ID: 33957339
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A medicare database analysis of practice patterns in patients with mantle cell lymphoma.
    Weaver JA; Peng Y; Ji Y; Gilbertson D; Pease DF; Morrison VA
    J Geriatr Oncol; 2021 Jul; 12(6):894-901. PubMed ID: 33423932
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Lyu M; Jiang E; He Y; Yang D; Ma Q; Pang A; Zhai W; Wei J; Huang Y; Zhang G; Zhang R; Feng S; Han M
    Hematology; 2021 Dec; 26(1):65-74. PubMed ID: 33402056
    [No Abstract]    [Full Text] [Related]  

  • 8. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
    Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
    Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer.
    Lu S; Zhang J; Ye M; Wang B; Wu B
    Pharmacogenomics; 2016 Jun; 17(9):985-94. PubMed ID: 27266545
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Serum free light chain response after 2 courses of induction chemotherapy predicts prognosis in myeloma patients.
    Yağcı M; Karakaya F; Suyanı E; Haznedar R
    Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):98-102. PubMed ID: 25441109
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.
    Hahn T; McCarthy PL; Hassebroek A; Bredeson C; Gajewski JL; Hale GA; Isola LM; Lazarus HM; Lee SJ; Lemaistre CF; Loberiza F; Maziarz RT; Rizzo JD; Joffe S; Parsons S; Majhail NS
    J Clin Oncol; 2013 Jul; 31(19):2437-49. PubMed ID: 23715573
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner.
    Graf N; Herrmann K; Numberger B; Zwisler D; Aichler M; Feuchtinger A; Schuster T; Wester HJ; Senekowitsch-Schmidtke R; Peschel C; Schwaiger M; Keller U; Dechow T; Buck AK
    Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):34-43. PubMed ID: 23053327
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Prognostic significance of serum proangiogenic molecules in patients with de novo non-Hodgkin lymphomas.
    Rujirojindakul P; Lekhakula A
    ScientificWorldJournal; 2012; 2012():215231. PubMed ID: 22629121
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Population-based study of trends and variations in radiotherapy as part of primary treatment of cancer in the southern Netherlands between 1988 and 2006, with an emphasis on breast and rectal cancer.
    Vulto JC; Lybeert ML; Louwman MW; Poortmans PM; Coebergh JW
    Int J Radiat Oncol Biol Phys; 2009 Jun; 74(2):464-71. PubMed ID: 19289268
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. treatment of relapsed or refractory aggressive non-hodgkin lymphoma with two ifosfamide-based regimens, IMVP and ICE.
    Aurer I; Mitrović Z; Nemet D; Radman I; Sertić D; Serventi-Seiwerth R; Stern-Padovan R; Santek F; Nola M; Mrsić M; Labar B
    J Chemother; 2008 Oct; 20(5):640-4. PubMed ID: 19048695
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Plasma cytokine and soluble receptor signature predicts outcome of patients with classical Hodgkin's lymphoma: a study from the Groupe d'Etude des Lymphomes de l'Adulte.
    Casasnovas RO; Mounier N; Brice P; Divine M; Morschhauser F; Gabarre J; Blay JY; Voillat L; Lederlin P; Stamatoullas A; Bienvenu J; Guiguet M; Intrator L; Grandjean M; Brière J; Ferme C; Salles G;
    J Clin Oncol; 2007 May; 25(13):1732-40. PubMed ID: 17389336
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. [Novel approaches to combination therapy of Hodgkin's disease].
    Kharchenko VP; Pan'shin GA; Datsenko PV; Sotnikov VM; Mel'nik IuD
    Vopr Onkol; 2005; 51(6):692-6. PubMed ID: 17037037
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The ratio between CD4+ and CD8+ cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide.
    Strupp C; Germing U; Aivado M; Kündgen A; Fenk R; Hünerlitürkoglu A; Kobbe G; Haas R; Gattermann N
    Leuk Lymphoma; 2005 Jul; 46(7):999-1006. PubMed ID: 16019550
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Bloodstream infections and invasive mycoses in children undergoing acute leukaemia treatment: a 13-year experience at a single Italian institution.
    Castagnola E; Caviglia I; Pistorio A; Fioredda F; Micalizzi C; Viscoli C; Haupt R
    Eur J Cancer; 2005 Jul; 41(10):1439-45. PubMed ID: 15963894
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
    Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
    Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.